About Syntimmune
Syntimmune is a company based in New York (United States) founded in 2013 was acquired by Alexion in September 2018. Syntimmune has raised $78 million across 5 funding rounds from investors including Alexion, Baxalta and Apple Tree Partners. Syntimmune operates in a competitive market with competitors including Moderna, BeiGene, Biogen, Incyte and ADMA Biologics, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Syntimmune
Syntimmune has successfully raised a total of $78M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Syntimmune
Syntimmune has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Alexion, Baxalta and Apple Tree Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Apple Tree Partners is engaged in life sciences venture capital.
|
Locked | Locked | Locked | |
|
Developer of therapies for orphan diseases and other disease conditions
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Syntimmune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Syntimmune
Investment portfolio details for Syntimmune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Syntimmune
Detailed financials for Syntimmune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Syntimmune Comparisons
Peer comparison for Syntimmune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Syntimmune
Syntimmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Biogen, Incyte and ADMA Biologics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
Detailed competitors of Syntimmune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Syntimmune
Complete news archive for Syntimmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Syntimmune
Syntimmune was founded in 2013.
Syntimmune is headquartered in New York, United States. It is registered at New York, New York, United States.
Syntimmune is a funded company, having raised a total of $78M across 5 funding rounds to date.
The company was founded in 2013 in New York, United States, within the biotechnology sector. Neonatal Fc receptor (FcRn) biology is investigated as a target for IgG-mediated autoimmune diseases. The lead program, SYNT001, consists of a biologic designed to block the FcRn-IgG interaction and is undergoing IND-enabling studies for one such disease. Two further programs addressing distinct elements of FcRn biology are under development.
Syntimmune has 4 investors. Key investors include Alexion, Baxalta, Apple Tree Partners, and Partners HealthCare.